Published in Drug Metab Dispos on December 09, 2009
First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci (2011) 1.27
Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos (2011) 1.11
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos (2010) 0.88
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos (2010) 0.83
Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics. Drug Metab Dispos (2013) 0.81
Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent. PLoS One (2013) 0.81
Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab Dispos (2011) 0.81
A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives. Drug Metab Dispos (2014) 0.79
A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2). Pharm Res (2012) 0.77
Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4. Sci Rep (2015) 0.76
Metabolism of androstenone, 17β-estradiol and dihydrotestosterone in primary cultured pig hepatocytes and the role of 3β-hydroxysteroid dehydrogenase in this process. PLoS One (2015) 0.75
Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol (2000) 4.87
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry (1998) 1.93
UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther (2005) 1.80
Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev (1999) 1.72
Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry (1994) 1.68
In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos (2000) 1.53
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos (2004) 1.51
In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos (2000) 1.36
Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol (2007) 1.35
Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos (2001) 1.29
In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol (2006) 1.20
In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos (2006) 1.20
Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol (2004) 1.13
CYP2E1 substrate inhibition. Mechanistic interpretation through an effector site for monocyclic compounds. J Biol Chem (2007) 1.13
Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos (1996) 1.10
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model. Drug Metab Dispos (2001) 1.08
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos (2005) 1.06
Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation. J Biol Chem (2006) 1.03
Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos (2002) 1.03
Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos (2006) 1.02
Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem (2008) 1.02
A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem (2000) 1.02
Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res (2006) 1.02
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos (2001) 0.98
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol (2008) 0.98
Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab Dispos (2002) 0.98
Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol (2005) 0.93
Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol (2004) 0.91
In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol (2009) 0.89
Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis (2005) 0.89
Resveratrol (trans-resveratrol, 3,5,4'-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos (2007) 0.89
The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos (2008) 0.87
Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos (2008) 0.86
Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol (2007) 0.84
Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. Drug Metab Dispos (2007) 0.84
Effects of beta-estradiol and propofol on the 4-methylumbelliferone glucuronidation in recombinant human UGT isozymes 1A1, 1A8 and 1A9. Biopharm Drug Dispos (2004) 0.83
Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Adv Exp Med Biol (2001) 0.79
Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol (2003) 1.86
Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos (2002) 1.45
Rat hepatocyte spheroids formed by rocked technique maintain differentiated hepatocyte gene expression and function. Hepatology (2009) 1.41
Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver. Liver Transpl (2005) 1.36
Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem (2005) 1.26
Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol (2007) 1.25
CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos (2006) 1.24
Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common. Drug Metab Dispos (2007) 1.21
Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos (2004) 1.19
Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol (2005) 1.19
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis (2005) 1.17
Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation. Drug Metab Dispos (2006) 1.11
Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations. Arch Biochem Biophys (2003) 1.11
Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Arch Biochem Biophys (2006) 1.08
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol (2005) 1.08
CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis. Drug Metab Dispos (2009) 1.07
CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus. Drug Metab Dispos (2010) 1.06
Your role and responsibilities in the manuscript peer review process. Am J Pharm Educ (2008) 1.05
Social network analysis to assess the impact of the CTSA on biomedical research grant collaboration. Clin Transl Sci (2014) 1.05
In vivo oxidative metabolism of a major peroxidation-derived DNA adduct, M1dG. Proc Natl Acad Sci U S A (2006) 1.04
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics (2010) 1.03
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients. Br J Clin Pharmacol (2003) 1.02
Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry (2004) 1.00
Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research. Pharmacotherapy (2008) 0.99
CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol (2005) 0.96
Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos (2004) 0.95
CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis. Drug Metab Dispos (2007) 0.93
Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos (2008) 0.92
Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos (2005) 0.92
Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity. Mol Pharmacol (2007) 0.92
Medication use in a rural gynecologic population: prescription, over-the-counter, and herbal medicines. Am J Obstet Gynecol (2004) 0.91
Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther (2006) 0.91
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose. J Pharmacol Exp Ther (2009) 0.91
High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry. Ther Drug Monit (2008) 0.90
High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.90
Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos (2002) 0.90
Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening. ChemMedChem (2010) 0.89
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics (2013) 0.88
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis. Bioorg Med Chem (2013) 0.88
Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab Dispos (2010) 0.88
Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9. J Am Chem Soc (2006) 0.87
Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos (2006) 0.87
Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes. Pharmacogenomics (2011) 0.86
Stability of heroin, 6-monoacetylmorphine, and morphine in biological samples and validation of an LC-MS assay for delayed analyses of pharmacokinetic samples in rats. J Pharm Biomed Anal (2012) 0.86
Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res (2006) 0.86
Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode. Drug Metab Dispos (2009) 0.86
Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics (2012) 0.84
Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metab Dispos (2004) 0.84
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry (2008) 0.84
Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. Drug Metab Dispos (2004) 0.84
Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles. Drug Metab Dispos (2006) 0.84
Measurement of electron transfer through cytochrome P450 protein on nanopillars and the effect of bound substrates. J Am Chem Soc (2013) 0.84
Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos (2010) 0.83
Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol (2004) 0.83
Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9. J Med Chem (2007) 0.82
Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Arch Biochem Biophys (2008) 0.82
Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos (2008) 0.82
Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol (2006) 0.81
The clinical pharmacokinetics of pyrazinamide in HIV-infected persons with tuberculosis. Clin Infect Dis (2004) 0.80
Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection. Drug Metab Dispos (2008) 0.80
The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites. Appl Biochem Biotechnol (2013) 0.79
Epoxidation of the methamphetamine pyrolysis product, trans-phenylpropene, to trans-phenylpropylene oxide by CYP enzymes and stereoselective glutathione adduct formation. Toxicol Appl Pharmacol (2005) 0.78
Gene expression and functional analyses of primary rat hepatocytes on nanofiber matrices. Cells Tissues Organs (2009) 0.78
Comparison of U.S. and Chinese pharmacy education programs. Am J Health Syst Pharm (2014) 0.78
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. Breast Cancer Res Treat (2006) 0.77
Localized delivery of chemotherapy to the cervix for radiosensitization. Gynecol Oncol (2012) 0.77
Excretion of the principal urinary metabolites of phenytoin and absolute oral bioavailability determined by use of a stable isotope in patients with epilepsy. Ther Drug Monit (2011) 0.77
Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes. Nanotechnology (2012) 0.77
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. Cancer Chemother Pharmacol (2012) 0.77
The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase. Drug Metab Dispos (2011) 0.77
Synthesis of deuterium-labelled 5'-O-[N-(Salicyl)sulfamoyl]adenosine (Sal-AMS-d(4)) as an internal standard for quantitation of Sal-AMS. J Labelled Comp Radiopharm (2008) 0.77
Different enzyme kinetic models. Methods Mol Biol (2014) 0.77
Nanoscale electron transport measurements of immobilized cytochrome P450 proteins. Nanotechnology (2015) 0.76
Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator. Drug Metab Dispos (2011) 0.76
Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice. Biochem Pharmacol (2005) 0.76
Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9. J Biomol Screen (2006) 0.76
Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol (2008) 0.76
A sensitive capillary GC-MS method for analysis of topiramate from plasma obtained from single-dose studies. Biomed Chromatogr (2012) 0.75
Identification of binding sites of non-I-helix water molecules in mammalian cytochromes p450. Drug Metab Dispos (2006) 0.75
Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.75
Case study 3. Application of basic enzyme kinetics to metabolism studies: real-life examples. Methods Mol Biol (2014) 0.75
Determination of constituents of Telazol--tiletamine and zolazepam by a gas chromatography/mass spectrometry-based method. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.75
Fundamentals of enzyme kinetics. Methods Mol Biol (2014) 0.75
Conversion of methamphetamine to N-methyl-methamphetamine in formalin solutions. J Anal Toxicol (2005) 0.75
EXTRACORPOREAL APPLICATION OF A GEL-ENTRAPMENT, BIOARTIFICIAL LIVER: DEMONSTRATION OF DRUG METABOLISM AND OTHER BIOCHEMICAL FUNCTIONS. Cell Transplant (1993) 0.75
Drug metabolism in hemorrhagic shock: pharmacokinetics of selective markers of cytochrome-P450 2C9, 2D6, and 3A4 enzyme activities in a porcine model. J Surg Res (2010) 0.75
Relative bioavailability, metabolism and tolerability of rectally administered oxcarbazepine suspension. Clin Drug Investig (2007) 0.75
Pharmacokinetic study in pigs and in vitro metabolic characterization in pig- and human-liver microsomes reveal marked differences in disposition and metabolism of tiletamine and zolazepam (Telazol). Xenobiotica (2013) 0.75